1. Home
  2. SPRO vs MHF Comparison

SPRO vs MHF Comparison

Compare SPRO & MHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.70

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$6.96

Market Cap

153.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
MHF
Founded
2013
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
153.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
MHF
Price
$2.70
$6.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
408.3K
47.6K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
4.29%
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
$16.23
N/A
Revenue Growth
39.24
N/A
52 Week Low
$0.65
$6.61
52 Week High
$3.09
$7.64

Technical Indicators

Market Signals
Indicator
SPRO
MHF
Relative Strength Index (RSI) 56.63 55.42
Support Level $2.15 $6.96
Resistance Level $2.70 $7.05
Average True Range (ATR) 0.14 0.08
MACD -0.01 0.01
Stochastic Oscillator 85.53 67.86

Price Performance

Historical Comparison
SPRO
MHF

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

Share on Social Networks: